Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

6825 ARTÍCULOS , VIENDO DEL 5911 AL 5925

Machine Learning for Predicting Cognitive Diseases: Methods, Data Sources and Risk Factors

Bratić B, Kurbalija V, Ivanović M, Oder I, Bosnić Z.

J Med Syst. 2018 Oct 27;42(12):243. doi: 10.1007/s10916-018-1071-x.

Implications of Successful Symptomatic Treatment in Parkinson's Disease for Therapeutic Strategies of Alzheimer's Disease

Zhao L, Cheng X, Zhong C.

ACS Chem Neurosci. 2019 Feb 20;10(2):922-930. doi: 10.1021/acschemneuro.8b00450. Epub 2018 Dec 12.

Acute inability to mobilise resulting from probable donepezil-induced myoclonus

Whateley JM, Huffman AJ, Henderson EJ.

Age Ageing. 2018 Nov 1;47(6):907-908. doi: 10.1093/ageing/afy093.

Early stage memory impairment, visual hallucinations, and myoclonus combined with temporal lobe atrophy predict Alzheimer's disease pathology in corticobasal syndrome

Jung NY, Lee JH, Lee YM, Shin JH, Shin MJ, Lee MJ, Pak K, Hwang C, Ahn JW, Sung S, Choi KU, Huh GY, Kim EJ.

Neurocase. 2018 Jun;24(3):145-150. doi: 10.1080/13554794.2018.1494290. Epub 2018 Jul 10.

Elimination of amyloid precursor protein in senile plaques in the brain of a patient with Alzheimer-type dementia and Down syndrome

Arai Y, Iwasaki Y, Suzuki T, Ide S, Kaga M.

Brain Dev. 2019 Jan;41(1):106-110. doi: 10.1016/j.braindev.2018.07.017. Epub 2018 Aug 4.

A novel presenilin 1 mutation (Leu418Trp) associated with spasticity, parkinsonism, and white matter lesion in a dominant Alzheimer's family

Takahashi Y, Ohta Y, Sasaki R, Tadokoro K, Sato K, Shang J, Takemoto M, Hishikawa N, Yamashita T, Haraguchi T, Ikeuchi T, Abe K.

J Neurol Sci. 2018 Apr 15;387:166-169. doi: 10.1016/j.jns.2018.01.006. Epub 2018 Jan 5.

Deep Brain Stimulation for Alzheimer's Disease

Xu DS, Ponce FA.

Curr Alzheimer Res. 2017;14(4):356-361. doi: 10.2174/1567205013666161014124945.

Redox-sensitive GFP to monitor oxidative stress in neurodegenerative diseases

Esposito S, Masala A, Sanna S, Rassu M, Pimxayvong V, Iaccarino C, Crosio C.

Rev Neurosci. 2017 Feb 1;28(2):133-144. doi: 10.1515/revneuro-2016-0041.

Future Directions in Imaging Neurodegeneration

Masdeu JC.

Curr Neurol Neurosci Rep. 2017 Jan;17(1):9. doi: 10.1007/s11910-017-0718-1.

Neuroinflammation as a Common Mechanism Associated with the Modifiable Risk Factors for Alzheimer's and Parkinson's Diseases

McKenzie JA, Spielman LJ, Pointer CB, Lowry JR, Bajwa E, Lee CW, Klegeris A.

Curr Aging Sci. 2017;10(3):158-176. doi: 10.2174/1874609810666170315113244.

A core avenue for transcultural research on dementia: on the cross-linguistic generalization of language-related effects in Alzheimer's disease and Parkinson's disease

Calvo N, Ibáñez A, Muñoz E, García AM.

Int J Geriatr Psychiatry. 2018 Jun;33(6):814-823. doi: 10.1002/gps.4712. Epub 2017 Mar 28.

In vivo ROS production and use of oxidative stress-derived biomarkers to detect the onset of diseases such as Alzheimer's disease, Parkinson's disease, and diabetes

Umeno A, Biju V, Yoshida Y.

Free Radic Res. 2017 Apr;51(4):413-427. doi: 10.1080/10715762.2017.1315114. Epub 2017 Apr 25.

Loss of gait control assessed by cognitive-motor dual-tasks: pros and cons in detecting people at risk of developing Alzheimer's and Parkinson's diseases

Belghali M, Chastan N, Cignetti F, Davenne D, Decker LM.

Geroscience. 2017 Jun;39(3):305-329. doi: 10.1007/s11357-017-9977-7. Epub 2017 May 27.

Social inappropriateness in neurodegenerative disorders

Desmarais P, Lanctôt KL, Masellis M, Black SE, Herrmann N.

Int Psychogeriatr. 2018 Feb;30(2):197-207. doi: 10.1017/S1041610217001260. Epub 2017 Jul 10.

Atypical parkinsonian syndromes: a general neurologist's perspective

Deutschländer AB, Ross OA, Dickson DW, Wszolek ZK.

Eur J Neurol. 2018 Jan;25(1):41-58. doi: 10.1111/ene.13412. Epub 2017 Sep 28.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias